Use of salusin β for predicting atherosclerosis and components of the metabolic syndrome
Advances in Clinical and Experimental Medicine · 2023
DOI: 10.17219/acem/166535 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Clinical and Experimental Medicine, 2023. Verfasst von Aleksandra Janecka und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Haematology and Oncology, Faculty of Medicine, Medical University of Gdansk, Poland. Hauptthemen laut MEDLINE: Atherosclerosis, Hyperglycemia, Hypertension, Metabolic Syndrome. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics, Haematology and Oncology, Faculty of Medicine, Medical University of Gdansk, Poland.
- Department of Paediatrics, Haematology and Oncology, University Clinical Centre, Gdańsk, Poland.
- Faculty of Health Sciences with Institute of Maritime and Tropical Medicine, Medical University of Gdansk, Poland.
Zitieren
APA
Janecka, A., & Stefanowicz, J. (2023). Use of salusin β for predicting atherosclerosis and components of the metabolic syndrome. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/166535
Vancouver
Janecka A, Stefanowicz J. Use of salusin β for predicting atherosclerosis and components of the metabolic syndrome. Advances in Clinical and Experimental Medicine. 2023. doi:10.17219/acem/166535
BibTeX
@article{Janecka2023,
author = {Janecka, Aleksandra and Stefanowicz, Joanna},
title = {Use of salusin β for predicting atherosclerosis and components of the metabolic syndrome},
journal = {Advances in Clinical and Experimental Medicine},
year = {2023},
doi = {10.17219/acem/166535}
}
EUVIMED